dihydroergotamine has been researched along with Liver Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, A; Chen, L; Dai, X; He, M; Li, S; Lian, J; Liao, Q; Liu, D; Shan, M; Sun, L; Xiang, L; Yang, M; Zhai, L; Zhang, Y | 1 |
1 other study(ies) available for dihydroergotamine and Liver Neoplasms
| Article | Year |
|---|---|
Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Dihydroergotamine; Humans; Liver Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Phenylurea Compounds; Sorafenib | 2023 |